摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪 | 425378-66-1

中文名称
3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪
中文别名
——
英文名称
3-trifluoromethyl-imidazo[1,2-b][1,2,4]triazine
英文别名
3-trifluoromethylimidazo[1,2-b][1,2,4]triazine;3-(trifluoromethyl)imidazo[1,2-b][1,2,4]triazine
3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪化学式
CAS
425378-66-1
化学式
C6H3F3N4
mdl
MFCD09031758
分子量
188.112
InChiKey
JHYXTDFPLCVQGD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    43.1
  • 氢给体数:
    0
  • 氢受体数:
    6

SDS

SDS:2ff0db52f17f79fc59320058633f2a35
查看

反应信息

  • 作为反应物:
    描述:
    3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪四(三苯基膦)钯sodium acetatesodium carbonate溶剂黄146 作用下, 以 四氢呋喃 为溶剂, 反应 22.0h, 生成 4,2'-Difluoro-5'-(3-trifluoromethyl-imidazo[1,2-b][1,2,4]triazin-7-yl)-biphenyl-2-carbonitrile
    参考文献:
    名称:
    Discovery of Imidazo[1,2-b][1,2,4]triazines as GABAA α2/3 Subtype Selective Agonists for the Treatment of Anxiety
    摘要:
    The identification of a series of imidazo[1,2-b][1,2,4]triazines with high affinity and functional selectivity for the GABA(A) alpha 3-containing receptor subtype is described, leading to the identification of a clinical candidate, 11. Compound 11 shows good bioavailability and half-life in preclinical species, and it is a nonsedating anxiolytic in both rat and squirrel monkey behavioral models.
    DOI:
    10.1021/jm051200u
  • 作为产物:
    描述:
    5-三氟甲基-[1,2,4]噻嗪-3-胺2-溴-1,1-二乙氧基乙烷氢溴酸 作用下, 反应 45.0h, 以22%的产率得到3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪
    参考文献:
    名称:
    [EN] IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
    [FR] DERIVES D'IMIDAZO-TRIAZINE UTILISES EN TANT QUE LIGANDS DES RECEPTEURS GABA
    摘要:
    一类7-苯基咪唑并[1,2-b][1,2,4]三嗪衍生物,其在苯环的间位被一个可选择取代的芳基或杂环芳基基团取代,该基团直接连接或通过氧原子或-NH-键连接,且在苯环上被本文所定义的一个或两个进一步取代基所取代,作为GABAA受体的选择性配体,特别具有对其α2和/或α3和/或α5亚基有良好亲和力,因此对于治疗和/或预防中枢神经系统的不良状况,包括焦虑、抽搐和认知障碍具有益处。
    公开号:
    WO2003093272A1
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS<br/>[FR] UTILISATION DE DERIVES D'IMIDAZO-TRIAZINE COMME LIGANDS DES RECEPTEURS GABA
    申请人:MERCK SHARP & DOHME
    公开号:WO2003093273A1
    公开(公告)日:2003-11-13
    A class of imidazo[1,2b][1,2,4]triazine derivatives, substituted at the 7-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    一类咪唑[1,2b][1,2,4]三嗪生物,通过在7位被一个可选择取代的五元或六元杂芳环取代,作为GABAA受体的选择性配体,特别对其α2和/或α3和/或α5亚基具有良好的亲和力,因此在治疗和/或预防中枢神经系统的不良症状,包括焦虑、抽搐和认知障碍方面具有益处。
  • Imidazo-triazine derivatives as ligands for GABA receptors
    申请人:——
    公开号:US20030055060A1
    公开(公告)日:2003-03-20
    A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by a (cyano)(fluoro)phenyl moiety, being selective ligands for GABA A receptors, in particular having good affinity for the &agr;2 and/or &agr;3 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety and convulsions.
    一类7-苯基咪唑[1,2-b][1,2,4]三嗪衍生物,通过在苯环的间位上取代(基)(基)苯基基团,作为GABA受体的选择性配体,特别是对其α2和/或α3亚基具有良好的亲和力,因此对于治疗和/或预防中枢神经系统的不良症状,包括焦虑和惊厥,具有益处。
  • Imidazo-triazine derivatives as ligands for gaba receptors
    申请人:Bettati Michela
    公开号:US20050165023A1
    公开(公告)日:2005-07-28
    A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and substituted on the phenyl ring by one or two further substituents as defined herein, being selective ligands for GABA A receptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    一类7-苯基咪唑[1,2-b][1,2,4]三嗪生物,苯环的间位被一个可选择取代的芳基或杂环芳基基团取代,该基团直接连接或由氧原子或-NH-键桥接,并在苯环上进一步取代一个或两个定义如下的取代基,是选择性的GABAA受体配体,特别是对其中的α2和/或α3和/或α5亚基具有良好的亲和力,因此对于治疗和/或预防中枢神经系统不良症状,包括焦虑、惊厥和认知障碍具有益处。
  • Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands
    申请人:Bettati Michela
    公开号:US20060040940A1
    公开(公告)日:2006-02-23
    The present invention provides a pharmaceutical composition providing a compound of formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable excipient: (I), in which: X and Y independently represent CH or N, with the proviso that if X is CH then Y is also CH; R 1 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, —OR a , —SR a , —SOR a , —SO 2 R a , —SO 2 NR a R b , —NR a R b , —NR a COR b , —NR a CO 2 R b , —COR a , —CO 2 R a , —CONR a R b or CR a ═NOR b ; R a and R b independently represent hydrogen, hydrocarbon or a heterocyclic group; V and W are independently selected from H, halogen, C 11-6 alkyl, OH and C -1-6 alkoxy; Z represents H, halogen, CN, NO 2 , CF 3 , OCF 3 , CF 2 H, SCF 3 , R 2 , OR 3 , SR 3 , (CH 2 )pN(R 3 ) 2 , O(CH 2 )pN(R 3 ) 2 , SO 2 R 2 , SO 2 N(R 3 ) 2 , COR 4 , CO 2 R 3 , CON(R 3 ) 2 , NHCOR 4 , NR 1 (CH 2 ) n heteroaryl or O(CH 2 ) n heteroaryl the heteroaryl is optionally substituted by one, two or three groups chosen from C 1-6 alkyl, benzyl, (CH 2 )pN(R 3 ) 2 , halogen and CF 3 , R 1 is C 1-6 alkyl, where n is 1 or 2 and p is 0, 1 or 2; with the proviso that at least one of V, W and Z is other than H; R 2 represents C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-4 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or heteroaryl, any of which may bear a substituent selected from halogen, CN, NO 2 , CF 3 , OCF 3 , CF 2 H, SCF 3 , OH, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, amino, C 1-4 alkylamino, or di(C 1-4 alkyl)amino; R 3 represents H or R 2 ; or two R 3 groups bonded to the same nitrogen atom may complete a 5-7 membered nonaromatic heterocyclic ring; and R 4 represents R 3 or heteroaryl; the compounds are ligands for GABA-A receptors containing the alpha 5 subtype and thus are useful for enhancing cognition in individuals suffering from conditions such as Alzheimer's Disease.
    本发明提供了一种制药组合物,其中包含式I的化合物或其药学上可接受的盐,以及药学上可接受的载体:(I),其中:X和Y独立地表示CH或N,但如果X是CH,则Y也是CH;R1表示氢、碳氢化合物、杂环基、卤素、基、三甲基、硝基、—ORa、—SRa、—SORa、—SO2Ra、—SO2NRaRb、—NRaRb、—NRaCORb、—NRaCO2Rb、—CORa、—CO2Ra、—CONRaRb或CRa═NORb;Ra和Rb独立地表示氢、碳氢化合物或杂环基;V和W独立地选自H、卤素、C11-6烷基、OH和C-1-6烷氧基;Z表示H、卤素、CN、NO2CF3、O 、CF2H、S 、R2、OR3、SR3、(CH2)pN(R3)2、O( )pN(R3)2、SO2R2、SO2N(R3)2、COR4、CO2R3、CON(R3)2、NHCOR4、NR1( )n杂环基或O( )n杂环基,其中杂环基可选地被来自C1-6烷基、苯甲基、( )pN(R3)2、卤素和 的一个、两个或三个基团取代,R1是C1-6烷基,其中n为1或2,p为0、1或2;但要求V、W和Z中至少有一个不是H;R2表示C1-6烷基、C3-6环烷基、C3-6环烷基C1-4烷基、C2-6烯基、C2-6炔基或杂环基,其中任何一种可以携带来自卤素、CN、 、 、O 、CF2H、S 、OH、C1-4烷氧基、C1-4烷氧羰基、基、C1-4烷基基或二(C1-4烷基)基的取代基;R3表示H或R2;或者两个结合到同一氮原子上的R3基团可以形成一个5-7成员非芳香杂环环;R4表示R3或杂环基;这些化合物是GABA-A受体的配体,包含α5亚型,因此对于患有阿尔茨海默病等疾病的个体,有助于增强认知能力。
  • PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS
    申请人:SYNGENTA PARTICIPATIONS AG
    公开号:US20160255837A1
    公开(公告)日:2016-09-08
    Pesticidally active bi- or tricyclic heterocycles with sulphur-containing substituents, stereoisomers and tautomeric forms thereof that can be used as insecticides and can be prepared in a manner known per se.
    具有含取代基的双环或三环杂环的杀虫活性化合物,其立体异构体和互变异构体可以用作杀虫剂,并可以采用已知的方法制备。
查看更多

同类化合物

咪唑并[1,2-b][1,2,4]三唑并[4,3-D][1,2,4]三嗪 3-甲基咪唑并[1,2-b][1,2,4]噻嗪 3-溴-7-甲基咪唑并[1,2-b][1,2,4]三嗪 3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪 2-咪唑并[1,2-B][1,2,4]三嗪-7-丙烷-2-醇 2-(3-溴咪唑并[1,2-b][1,2,4]-7-三嗪)丙烷-2-醇 3-(3-methylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2-imidazo[1,2-b][1,2,4]triazin-3-ylpropan-2-ol hydrochloride 2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol 2-(2,4-difluorophenyl)-6-((pyridin-2-yloxy)methyl)imidazo[1,2-b][1,2,4]triazine 2-(4-fluorophenyl)-7-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,2-b]-[1,2,4]-triazine 7-Bromo-2-methylimidazo[1,2-b][1,2,4]triazine 1,2,3,4-tetrahydro-dibenzo[4,5:e]imidazo[1,2-b][1,2,4]triazine 2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester 2-(imidazo[1,2-b][1,2,4]triazin-6-yl)ethanol 2-(4-fluorophenyl)-7-(4-methoxybenzyl)imidazo[1,2-b][1,2,4]triazine 7,9-Dimethylimidazo[1,2-b][1,2,4]benzotriazine 7-Methylimidazo[1,2-b][1,2,4]benzotriazine 7-Methoxyimidazo[1,2-b][1,2,4]benzotriazine imidazo[1,2-b][1,2,4]triazine-6-carbaldehyde 3-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-b][1,2,4]triazin-7-amine 7-nitro-3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine Imidazo[1,2-b][1,2,4]triazin-2(1H)-one 6-(3-Methoxycyclohexyl)-2-phenylimidazo[1,2-b][1,2,4]triazine 3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2,3-diphenyl-6-thiophen-2-yl-imidazo[1,2-b][1,2,4]triazine 7-(2-chloropyridin-4-yl)-3-trifluoromethylimidazo[1,2-b][1,2,4]triazine 3-(1-fluoro-1-methylethyl)imidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 6-(5-Chlorothiophen-2-yl)-2,3-dimethylimidazo[1,2-b][1,2,4]triazine 6-(5-Bromothiophen-2-yl)-2,3-dipyridin-2-ylimidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-ethyl-2-ethylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 2-(5-{7-[2-(difluoromethoxy)benzyl]-6-methylimidazo[1,2-b][1,2,4]triazin-2-yl}-pyrimidin-2-yl)propan-2-ol 2-[2-Chloro-4-[2-[2-cyclopentyl-5-(imidazo[1,2-b][1,2,4]triazin-6-ylmethyl)-4,6-dioxooxan-2-yl]ethyl]phenyl]-2-methylpropanenitrile (7E)-3-methyl-2-methylidene-7-[(2,3,4-trimethoxyphenyl)methylidene]-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(2-chloro-6-fluorophenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (3Z)-3-[(3-methoxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12Z)-12-[(2,4-dichlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(4-chlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (3E)-3-(thiophen-2-ylmethylidene)-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[[4-(dimethylamino)phenyl]methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (7E)-7-[(2-methoxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(3,4-dihydroxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[(3,4,5-trimethoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(2-methoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one 2-(Azepan-1-yl)-3-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-b][1,2,4]triazine 4-[(11-Hydroxy-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-12-yl)methylidene]-2-methoxycyclohexa-2,5-dien-1-one 2-(1-Adamantyl)-6,7,8,9-tetrahydroimidazo[1,2-b][1,2,4]benzotriazine 6-[1-(Furan-2-ylmethyl)-2,5-dimethylpyrrol-3-yl]-2,3-diphenylimidazo[1,2-b][1,2,4]triazine